厚樸酚及和厚樸酚是來(lái)自于中藥厚樸的同分異構(gòu)體，具有相同的藥理活性。它們都可通過(guò)保護(hù)胰腺β-細(xì)胞，促進(jìn)胰島素分泌，提高血中胰島素水平及細(xì)胞對(duì)葡萄糖的攝取和利用，從而降低胰島素抵抗和血糖水平；還能通過(guò)抑制脂質(zhì)合成和促進(jìn)脂質(zhì)分解，產(chǎn)生調(diào)血脂作用。厚樸酚及和厚樸酚可通過(guò)降血糖、調(diào)血脂及抗氧化作用，從源頭上減少氧化低密度脂蛋白（ox-LDL）和晚期糖基化終末產(chǎn)物（AGEs）的生成，還可通過(guò)抗氧化、抗炎及細(xì)胞保護(hù)作用，保護(hù)心血管系統(tǒng)、腎臟、肝臟、胰腺等組織器官對(duì)抗高血糖、高脂血癥誘導(dǎo)并發(fā)癥的發(fā)生和發(fā)展。因此厚樸酚及和厚樸酚有開(kāi)發(fā)成為治療代謝綜合征新藥的潛力。

Magnolol and honokiol are same structural isomers from Magnoliae Officinalis Cortex, and have same pharmacologic activity. Magnolol and honokiol decrease insulin resistance and glycemia level by protecting pancreatic β-cells, promoting secretion of insulin, increasing insulin level in blood and cell ability to take in and utilize glucose. Magnolol and honokiol have the effects of decreasing hyperlipemia by inhibiting lipidic synthesis and accelerating lipidic catabolism. Their mechanisms to prevent and treat for the complications of hyperglycemia and hyperlipemia are: the effects of magnolol and honokiol on hypoglycemia, hypolipemia and antioxidation decrease the products of AGEs and ox-LDL from source; the effects on antioxidation, anti-inflammation and cellar protection of magnolol and honokiol protect the organs of cardiovascullar system, ren, liver and pancreas against development of complications induced by hyperglycemia and hyperlipemia. So magnolol and honokiol have potentiality to become drugs of treating metabolic syndrome.